human
norovirus
predomin
etiolog
agent
acut
gastroenter
worldwid
estim
caus
gastroenter
case
global
approxim
million
infect
per
noroviru
respons
estim
death
largest
proport
occur
children
lower
incom
diseas
usual
symptom
diarrhea
vomit
nausea
fever
abdomin
cramp
usual
resolv
within
two
four
day
healthi
human
noroviru
affect
peopl
age
demograph
howev
increas
infect
rate
occur
within
group
neonat
elderli
immunocompromis
immunocompromis
transplant
recipi
would
benefit
antivir
noroviru
infect
persist
year
case
noroviru
infect
transplant
set
major
health
concern
transmiss
human
noroviru
primarili
occur
also
contamin
food
noroviru
highli
contagi
low
infecti
dose
estim
rang
viral
particl
outbreak
particularli
common
close
set
nurs
home
hospit
restaur
cruis
ship
social
cater
event
center
within
prolong
shed
noroviru
post
infect
could
also
contribut
noroviru
spread
report
mechan
nosocomi
reduc
noroviru
transmiss
prophylact
antivir
prevent
outbreak
essenti
protect
group
world
health
organ
global
estim
burden
foodborn
diseas
found
noroviru
common
caus
death
foodborn
also
respons
death
children
five
year
statist
associ
lower
incom
nation
basic
sanit
wastewat
infrastructur
often
lack
contribut
high
level
viral
transmiss
social
burden
reflect
substanti
econom
impact
noroviru
infect
estim
incur
usd
billion
direct
annual
health
cost
billion
societ
cost
worldwid
factor
forc
busi
closur
hospit
day
addit
noroviru
infect
recogn
fourth
greatest
caus
life
year
across
social
econom
impact
justifi
intens
research
undertaken
identifi
effect
antivir
vaccin
solut
human
noroviru
human
noroviru
classifi
within
calicivirida
divers
famili
rna
virus
current
divid
five
accept
genera
includ
noroviru
sapoviru
vesiviru
lagoviru
sever
addit
genera
noroviru
genu
classifi
seven
genogroup
genogroup
contain
numer
genotyp
base
capsid
polymeras
protein
code
sequenc
recombin
virus
differ
polymeras
capsid
genotyp
mani
virus
detect
today
recombin
genogroup
gi
gii
giv
norovirus
infect
human
gii
norovirus
respons
approxim
noroviru
infect
particular
genogroup
ii
genotyp
strain
recogn
caus
major
gii
noroviru
global
case
histor
respons
six
report
pandem
tempor
order
includ
us
variant
farmington
hill
variant
hunter
den
haag
new
orlean
sydney
norovirus
persist
domin
strain
circul
worldwid
number
virus
genotyp
emerg
recent
year
exampl
sudden
increas
high
preval
strain
asian
countri
occur
although
high
preval
strain
reflect
part
world
lower
level
detect
australasia
europ
north
america
compar
asian
outbreak
human
noroviru
rna
genom
kb
figur
encapsid
within
nonenvelop
icosahedr
nm
virion
genom
three
open
read
frame
orf
encod
polyprotein
posttransl
cleav
seven
nonstructur
protein
ntpase
vpg
viral
proteas
pro
viral
rna
polymeras
rdrp
cystein
proteas
figur
review
karst
et
encod
protein
respect
major
capsid
protein
minor
capsid
protein
like
involv
capsid
assembl
genom
protein
structur
compris
shell
protrud
p
domain
domain
enclos
viral
rna
antigen
variabl
p
domain
form
outer
surfac
also
involv
cell
protein
express
baculoviru
particl
vlp
vlp
antigen
structur
indistinguish
virion
produc
complet
despit
clinic
signific
noroviru
infect
antivir
studi
hinder
recent
human
noroviru
could
success
propag
cell
cultur
recent
breakthrough
enabl
human
noroviru
cultur
b
intestin
repres
mileston
field
noroviru
biolog
howev
modest
replic
level
gener
new
system
log
increas
b
log
increas
mean
requir
optim
widespread
use
antivir
screen
develop
norwalk
viru
noroviru
replicon
system
use
assess
antivir
candid
human
viru
lieu
viral
cultur
system
figur
norwalk
replicon
consist
intact
genom
end
howev
disrupt
neomycin
gene
engin
region
subgenom
promot
preserv
express
intact
disrupt
stabli
express
cell
cell
norwalk
replicon
proven
use
tool
screen
potenti
antivir
compound
tabl
howev
replic
level
norwalk
replicon
rel
low
approxim
norwalk
rna
copi
per
compar
replicon
system
hepat
c
viru
hcv
hcv
replicon
typic
yield
copi
per
cell
aa
eltahla
person
commun
use
identifi
mani
success
antivir
candid
moreov
amen
antivir
screen
review
horscroft
et
directli
led
mani
antivir
daa
use
treat
hcv
infect
today
review
asselah
et
model
also
use
studi
antivir
efficaci
noroviru
figur
exampl
research
use
vitro
enzym
activ
assay
viral
polymeras
proteas
figur
screen
compound
antivir
activ
addit
crystallographi
silico
model
use
examin
ligand
viral
protein
interact
elucid
antivir
surrog
virus
within
calicivirida
famili
also
exploit
screen
inhibitori
activ
antivir
candid
across
sever
caliciviru
genera
figur
surrog
includ
murin
noroviru
mnv
noroviru
felin
caliciviru
fcv
vesiviru
porcin
sapoviru
sapoviru
rabbit
hemorrhag
diseas
viru
rhdv
lagoviru
tulan
viru
propos
genu
mnv
particular
use
predomin
human
noroviru
surrog
classifi
within
genu
robustli
propag
cell
make
amen
viral
disinfect
steril
addit
featur
make
mnv
desir
antivir
screen
includ
abil
manipul
revers
genet
whilst
vivo
studi
mice
mani
genet
background
variou
anim
model
also
use
human
noroviru
challeng
studi
includ
nonhuman
primat
chimpanze
macaqu
marmoset
addit
gnotobiot
miniatur
pig
gnotobiot
also
use
well
knockout
human
mice
noroviru
infect
howev
anim
model
deem
entir
suitabl
due
obviou
differ
clinic
diseas
gut
physiolog
microbiom
naiveti
noroviru
infect
compar
human
popul
low
genet
divers
laboratori
test
everi
stage
human
noroviru
replic
cycl
repres
uniqu
target
antivir
develop
figur
howev
develop
antivir
therapi
target
viral
replic
requir
detail
understand
noroviru
biolog
viral
gene
function
much
still
elucid
overview
human
noroviru
lifecycl
specif
antivir
target
outlin
figur
stage
replic
cycl
antivir
target
includ
host
cell
attach
intern
genom
releas
viral
genom
replic
mediat
viral
rdrp
translat
genom
subgenom
templat
use
vpg
host
cell
machineri
viral
proteas
cleavag
viral
polyprotein
yield
matur
viral
protein
follow
assembl
packag
cell
egress
review
thorn
number
noroviru
antivir
report
publish
last
three
signific
recent
progress
field
warrant
updat
review
herein
includ
comprehens
overview
studi
sinc
includ
antivir
candid
examin
least
two
differ
system
eg
viral
enzym
inhibit
assay
mnv
cell
cultur
note
plant
food
extract
antinoroviru
effect
omit
studi
activ
antivir
compound
unknown
review
focus
compound
defin
structur
outlin
tabl
includ
studi
use
recent
develop
human
noroviru
cell
cultur
system
b
also
discuss
recent
identifi
antivir
antinoroviru
activ
provid
comprehens
overview
compound
recent
novel
excit
area
within
noroviru
antivir
research
tabl
tabl
list
individu
antivir
compound
case
sever
similar
deriv
studi
list
potent
compound
group
repres
deriv
relev
citat
compound
index
clariti
throughout
manuscript
tabl
cell
attach
entri
featur
viral
replic
cycl
extens
investig
antivir
target
human
immunodefici
viru
hiv
dengu
viru
denv
amongst
other
design
compound
capabl
target
viral
entri
knowledg
viral
entri
receptor
usual
requir
recent
identifi
entri
receptor
mnv
howev
counterpart
receptor
human
noroviru
yet
absenc
antivir
target
noroviru
entri
bia
toward
compound
prevent
noroviru
cellular
attach
wide
studi
attach
target
group
antigen
hbga
hbga
complex
carbohydr
present
abundantli
surfac
mucos
epithelia
gastrointestin
tract
interact
surfac
domain
capsid
thought
aid
viral
attach
perhap
even
hbga
determin
host
cell
genet
review
tan
play
import
role
term
viru
host
interact
norovirus
initi
one
studi
silico
screen
perform
drug
librari
million
compound
identifi
molecul
interact
strongli
hbga
prevent
noroviru
potenti
hit
n
confirm
vitro
immunosorb
assay
elisa
human
noroviru
block
assay
reveal
compound
phenanthren
base
structur
n
display
potent
inhibit
potent
compound
seri
approxim
studi
other
use
assay
shown
human
milk
oligosaccharid
hmo
fl
inhibit
bind
noroviru
vlp
hbga
low
millimolar
concentr
mm
later
shown
also
inhibit
bind
vlp
hbga
valu
rang
mm
mm
similar
fashion
citric
acid
shown
bind
noroviru
vlp
caus
alter
morpholog
prevent
addit
crystallographi
reveal
hmo
interact
directli
p
domain
capsid
thu
provid
clear
mechan
bind
inhibit
despit
advanc
attach
inhibitor
test
vlp
less
common
genotyp
thu
effect
broader
spectrum
noroviru
strain
need
demonstr
passiv
immunotherapi
monoclon
antibodi
mab
nanobodi
nb
antivir
strategi
prevent
noroviru
attach
entri
would
particularli
use
immunocompromis
patient
therapeut
mab
gener
human
chimpanze
b
cell
describ
sever
studi
shown
block
carbohydr
bind
noroviru
howev
mab
shown
provid
protect
norwalk
viru
infect
chimpanze
tabl
despit
mab
gener
thu
far
limit
activ
make
less
optim
antivir
antigen
divers
noroviru
recent
nb
shown
broadli
neutral
activ
vlp
import
noroviru
genotyp
via
interact
capsid
p
nanobodi
recombin
camelid
antibodi
fragment
kda
bind
high
affin
specif
antigen
review
harmsen
de
noroviru
nb
broad
bind
capabl
vlp
prevent
attach
activ
display
nb
illustr
molecul
potenti
overcom
narrow
antigen
spectrum
typic
display
convent
mab
howev
despit
find
mab
nb
studi
base
mostli
structur
analysi
bind
tabl
thu
effect
compound
noroviru
cell
cultur
vivo
need
explor
continu
develop
toward
clinic
applic
na
inhibit
rna
synthesi
mimicri
incom
nucleosid
triphosph
ntp
upon
incorpor
subsequ
caus
chain
less
commonli
increas
mutat
viral
genom
transcript
result
lethal
mutagenesi
also
known
error
catastroph
sinc
na
bind
highli
conserv
rdrp
activ
site
gener
demonstr
antivir
activ
compar
nni
therefor
na
develop
rna
virus
examin
repurpos
human
noroviru
therapeut
term
noroviru
intens
studi
initi
develop
antivir
therapi
hcv
chain
termin
cytidin
analog
vitro
activ
flavivirus
includ
denv
yellow
fever
viru
west
nile
howev
develop
oral
prodrug
valopicitabin
halt
use
hcv
follow
report
undesir
gastrointestin
side
despit
discontinu
clinic
develop
still
wide
report
potenti
noroviru
antivir
one
studi
mnv
plaqu
format
rna
synthesi
inhibit
valu
also
found
reduc
rna
synthesi
norwalk
replicon
fashion
anoth
studi
report
similar
potenc
mnv
rna
level
reduct
potenc
norwalk
replicon
found
higher
differ
propos
due
either
vari
methodolog
studi
differ
drug
human
noroviru
bjab
cell
cultur
system
inhibit
human
noroviru
replic
despit
variat
potenc
observ
vitro
system
collect
studi
illustr
polymeras
excel
antivir
target
inhibit
noroviru
replic
na
also
shown
promis
potenti
noroviru
antivir
mous
model
studi
knockout
mice
infect
mnv
treat
protect
mortal
diarrhea
reduc
noroviru
genom
titer
tissu
stool
reduct
compar
addit
mice
treat
high
dose
day
demonstr
reduc
transmiss
uninfect
sentinel
mice
cage
togeth
offer
prophylact
protect
attempt
improv
safeti
efficaci
therapi
sever
deriv
examin
antinoroviru
activ
exampl
one
studi
evalu
inhibitori
activ
nhc
hbvhiv
na
lamivudin
replic
mnv
norwalk
valu
mnv
cell
cultur
nhc
lamivudin
inhibitori
effect
replicon
rna
synthesi
inde
demonstr
inhibit
norwalk
replicon
rna
level
although
found
potent
search
continu
safer
deriv
treatment
noroviru
infect
effect
altern
identifi
thu
far
favipiravir
anoth
na
assess
potenti
antivir
human
noroviru
purin
shown
induc
lethal
mutagenesi
consist
result
approv
treatment
influenza
also
inhibit
replic
sever
virus
use
vitro
mous
model
includ
flavivirus
arenavirus
ebola
poor
antivir
activ
mnv
replic
cell
cultur
inhibit
cytopath
effect
rna
synthesi
therapeut
index
human
noroviru
replicon
also
use
examin
antivir
efficaci
exhibit
modest
despit
clinic
approv
influenza
display
level
potenc
like
low
pursu
noroviru
therapeut
anoth
na
examin
noroviru
ribavirin
rbv
rbv
antivir
activ
dna
rna
virus
use
clinic
treat
hcv
hepat
e
viru
lassa
fever
respiratori
syncyti
viru
amongst
other
review
guanosid
analog
rbv
first
shown
inhibit
human
noroviru
replicon
mnv
replic
around
norwalk
replicon
reduct
replicon
genom
level
compar
expect
na
bind
site
rbv
shown
polymeras
activ
site
cocrystal
studi
mnv
howev
rbv
poorli
inhibit
mnv
well
norwalk
replicon
rbv
exert
inhibitori
action
earli
mnv
effect
detect
hpi
moi
suggest
chain
termin
possibl
mode
na
howev
sequenc
mnv
popul
four
serial
passag
within
cell
line
presenc
rbv
show
increas
mutat
per
nucleotid
compar
untreat
observ
consist
report
rbv
multipl
mode
action
includ
mutagenesi
direct
inhibit
rna
polymeras
unbalanc
intracellular
ntp
pool
interfer
cap
structur
cap
despit
modest
inhibit
rbv
mnv
norwalk
replicon
coupl
numer
advers
effect
report
rbv
treatment
suggest
antivir
desir
antinoroviru
agent
novel
na
discov
ht
accord
manufactur
press
releas
potent
activ
reportedli
recruit
stage
phase
clinic
trial
evalu
safeti
toler
pharmacokinet
less
equal
healthi
adult
public
avail
write
review
result
project
releas
later
nni
gener
exhibit
antivir
activ
bind
alloster
block
conform
rearrang
viral
polymeras
requir
form
activ
replic
current
three
known
nni
bind
site
noroviru
rdrp
one
bind
pocket
within
ntp
access
path
locat
finger
thumb
second
pocket
term
site
posit
charg
ntp
travers
channel
flexibl
amino
acid
side
third
pocket
site
b
highli
conserv
alloster
bind
pocket
present
across
calicivirida
locat
within
thumb
figur
sever
therapeut
repurpos
nni
human
noroviru
one
exampl
includ
sleep
sick
medic
suramin
larg
symmetr
polyanion
naphthylurea
molecular
mass
gmol
suramin
found
potent
inhibit
vitro
activ
human
mnv
valu
nm
respect
similarli
smaller
suramin
deriv
inhibit
human
mous
noroviru
rdrp
activ
valu
nm
cocrystal
studi
compound
human
noroviru
polymeras
identifi
suramin
bind
pocket
within
ntp
pathway
finger
thumb
suramin
deriv
inhibit
vitro
noroviru
rdrp
transcript
naphthalen
disulfon
gmol
tetrasodium
salt
ppnd
gmol
ppnd
inhibit
human
noroviru
rdrp
enzym
assay
valu
respect
ppnd
also
inhibit
mnv
rdrp
cocrystal
studi
reveal
bind
site
site
b
ppnd
bind
sole
site
synchrotron
crystal
studi
group
confirm
ppnd
also
bind
alloster
within
site
b
mnv
rdrp
mimick
two
stack
rna
despit
promis
potenc
suramin
deriv
includ
ppnd
compound
demonstr
limit
bioavail
exhibit
poor
cell
greatli
reduc
antivir
efficaci
viral
suramin
shown
inhibit
mnv
replic
cell
cultur
larg
structur
low
cell
permeabl
meant
deliveri
requir
liposom
system
enter
similarli
ppnd
found
much
less
potent
mnv
cell
cultur
demonstr
inhibit
mnv
replic
plaqu
assay
compar
inhibit
concentr
rdrp
moreov
ppnd
elimin
enzym
inhibit
studi
due
nonspecif
therefor
like
unsuit
drug
candid
antinoroviru
develop
repurpos
antivir
develop
virus
sometim
reveal
drug
candid
activ
develop
recent
studi
evalu
antivir
activ
six
hcv
nni
human
noroviru
includ
filibuvir
lomibuvir
nesbuvir
setrobuvir
tegobuvir
use
fluoresc
polymeras
assay
hcv
nni
except
shown
activ
across
sever
genera
calicivirida
inhibit
human
noroviru
polymeras
mnv
replic
cell
cultur
caliciviru
rdrp
vitro
activ
assay
valu
rang
studi
ppnd
inhibit
human
mous
noroviru
rdrp
less
potent
previous
report
variat
like
due
differ
methodolog
noroviru
rdrp
mutant
studi
dock
studi
combin
antagon
ppnd
suggest
bind
site
within
highli
conserv
site
b
exploit
rdrp
bind
pocket
site
silico
screen
approxim
commerci
avail
compound
perform
identifi
ligand
bind
site
b
human
noroviru
mnv
compound
select
screen
assess
inhibit
human
noroviru
rdrp
reveal
hit
compound
synthesi
deriv
compound
produc
novel
candid
compound
valu
human
noroviru
rdrp
mnv
rdrp
silico
molecular
model
biolog
antagon
studi
ppnd
suggest
bind
site
compound
inde
within
target
site
b
pocket
howev
rel
ineffect
mnv
cell
cultur
issu
cell
permeabl
specif
compound
toxic
potenc
could
address
extens
medicin
chemistri
improv
druggabl
development
nni
sever
potenti
noroviru
nni
also
identifi
ht
compound
librari
use
viral
enzym
activ
assay
case
point
ht
almost
compound
rdrp
inhibit
use
fluoresc
activ
assay
eltahla
et
four
lead
compound
identifi
valu
human
noroviru
polymeras
rang
inhibit
norwalk
replicon
mnv
replic
cell
cultur
valu
nni
repres
scaffold
potenti
structur
modifi
increas
potenc
grow
bodi
research
invest
identifi
antivir
target
noroviru
polymeras
date
candid
still
earli
preclin
develop
search
compound
continu
earnest
much
like
rdrp
noroviru
proteas
figur
repres
desir
antivir
target
sinc
play
essenti
role
viral
replic
cleavag
ns
polyprotein
necessari
product
viral
progeni
noroviru
proteas
inhibitor
pi
test
wide
rang
model
antivir
system
figur
repres
class
caliciviru
antivir
number
compound
tabl
rupintrivir
one
first
pi
describ
noroviru
although
compound
origin
develop
human
rhinoviru
kim
et
demonstr
antivir
activ
rupintrivir
picornavirus
coronavirus
calicivirus
includ
mnv
fcv
norwalk
replicon
subsequ
studi
support
initi
observ
show
rupintrivir
inhibit
norwalk
replicon
valu
howev
case
pi
potenc
translat
vivo
exampl
rupintrivir
demonstr
poor
pharmacokinet
properti
limit
therefor
ideal
antinoroviru
therapi
remain
noroviru
pi
describ
literatur
mostli
develop
one
group
research
broadli
divid
transit
state
ts
inhibitor
ts
mimic
review
galas
et
ts
mimic
includ
eg
compound
effect
inhibit
norwalk
replicon
low
micromolar
although
potent
ts
mimic
far
less
studi
ts
inhibitor
repres
small
proport
compound
describ
tabl
first
ts
inhibitor
design
includ
seri
peptidyl
aldehyd
incorpor
glutamin
surrog
take
advantag
prefer
noroviru
proteas
cleav
peptid
within
origin
seri
peptidyl
aldehyd
n
compound
display
inhibit
mnv
infect
respect
norwalk
replicon
respect
sever
variant
primari
hit
develop
later
studi
includ
dipeptidyl
aldehyd
eg
compound
tripeptidyl
aldehyd
eg
peptidyl
eg
compound
eg
compound
bisulfit
adduct
eg
ester
carbam
prodrug
bilsulfit
adduct
eg
compound
variant
display
equal
greater
level
antivir
activ
compar
origin
peptidyl
aldehyd
inhibitor
potent
variant
display
low
nanomolar
potenc
mnv
vitro
vivo
norwalk
replicon
anoth
subclass
ts
inhibitor
includ
macrocycl
structur
modifi
version
aforement
ts
inhibitor
macrocycl
compound
origin
design
improv
membran
permeabl
oral
bioavail
ts
inhibitor
increas
suitabl
clinic
sever
studi
investig
inhibitori
effect
macrocycl
ts
inhibitor
rang
compound
well
rang
eg
compound
rang
eg
compound
rang
eg
compound
variant
norwalk
replicon
although
none
macrocycl
ts
inhibitor
reach
potenc
achiev
ts
inhibitor
sever
macrocycl
variant
display
antivir
activ
member
superclust
similar
effect
pi
across
multipl
genera
noroviru
genogroup
illustr
proteas
excel
antivir
candid
treatment
noroviru
infect
recent
explor
class
noroviru
antivir
includ
deubiquitinas
dub
dub
inhibitor
class
enzym
involv
regul
system
commonli
exploit
virus
replic
review
exampl
small
synthet
dub
inhibitor
molecular
weight
gmol
shown
effect
inhibit
mnv
noroviru
replic
induct
unfold
protein
howev
initi
studi
reveal
inhibit
mnv
mice
limit
small
intestin
due
poor
bioavail
address
poor
bioavail
librari
variant
develop
test
improv
antivir
deriv
compound
found
potent
treatment
deriv
result
reduct
replic
norwalk
replicon
reduct
mnv
titer
infect
cell
doubl
potenc
parent
anoth
host
protein
identifi
antivir
target
protein
molecular
chaperon
involv
matur
protein
respons
multipl
biolog
process
review
li
et
vashist
et
initi
show
use
sirna
knockdown
overexpress
studi
interact
termini
mnv
genom
play
key
role
mnv
author
show
abolish
activ
use
potent
inhibit
mnv
replic
vitro
nm
reduc
mnv
titer
vivo
mous
despit
potenti
cytotox
compound
review
engel
et
gener
therapeut
target
specif
host
protein
result
effect
antivir
activ
minim
effect
desir
featur
noroviru
therapeut
immunomodul
excel
therapeut
option
viru
infect
due
abil
induc
power
host
respons
intracellular
parasit
best
exampl
immunomodul
interferon
ifn
decad
studi
shown
type
ii
ifn
well
receptor
provid
protect
murin
human
noroviru
howev
role
type
iii
ifn
noroviru
infect
potenti
noroviru
antivir
recent
bind
heterodimer
receptor
compris
receptor
induc
express
mani
gene
induc
type
ii
howev
unlik
type
ii
ifn
singl
dose
shown
prevent
clear
persist
mnv
infect
shown
target
nonhematopoiet
intestin
epitheli
cell
express
high
level
use
mnv
transmiss
model
endogen
express
induc
use
transfect
plasmid
shown
block
mnv
transmiss
mice
infect
acut
mnv
treatment
also
prevent
intestin
replic
inflamm
antibodi
respons
illustr
integr
role
prevent
noroviru
transmiss
taken
togeth
antivir
activ
display
studi
reveal
potenti
therapeut
cure
infect
also
prevent
noroviru
spread
given
prophylact
recent
group
immunomodul
known
receptor
tlr
agonist
explor
noroviru
antivir
compound
use
mani
year
vaccin
adjuv
also
shown
inhibit
replic
rna
virus
hiv
tlr
agonist
induc
innat
immun
respons
stimul
ifn
product
known
antivir
activ
mnv
human
noroviru
sever
agonist
shown
display
potent
inhibit
mnv
infect
includ
nm
gardiquimod
therapeut
indic
furthermor
condit
media
gener
stimul
cell
reduc
replic
norwalk
replicon
recent
agonist
acid
explor
antivir
test
mnv
vitro
display
valu
addit
mgkg
dosag
mice
follow
mnv
infect
result
reduct
viral
given
agonist
monophospholipid
approv
use
adjuv
hpv
hbv
vaccin
review
dowl
agonist
alreadi
approv
treatment
genit
repurpos
agonist
could
huge
expedit
use
noroviru
clinic
treatment
sever
compound
demonstr
antivir
activ
mechan
inhibit
unknown
includ
molecul
theaflavin
digal
myricetin
among
mani
other
display
medicin
properti
although
display
limit
inhibit
noroviru
infect
mechan
action
flavonoid
noroviru
thought
result
pathway
activ
similarli
phytochem
curcumin
class
compound
display
inhibit
noroviru
howev
mechan
inhibit
poorli
understood
vitamin
shown
inhibit
mnv
vitro
albeit
poorli
less
inhibit
uml
inhibit
norwalk
replicon
uml
vitamin
chang
microflora
thought
mechan
respons
antivir
lastli
nitazoxanid
ntz
cover
section
shown
promis
antivir
therapi
defin
mechan
activ
noroviru
yet
determin
recent
ntz
shown
potent
inhibit
fcv
replic
cell
cultur
gi
noroviru
replicon
clinic
relev
concentr
later
shown
result
broad
antivir
despit
observ
latter
studi
also
show
ntz
ineffect
mnv
suggest
antivir
investig
date
noroviru
antivir
vaccin
approv
medic
use
noroviru
antivir
candid
complet
clinic
trial
ntz
compound
origin
develop
current
therapi
treat
giardia
crytosporidium
ntz
demonstr
antimicrobi
activ
rang
bacteri
protozoan
viral
infect
includ
inhibit
norwalk
replicon
review
phase
ii
random
trial
ntz
therapi
administ
patient
year
test
posit
rotaviru
noroviru
infect
treatment
result
signific
reduct
durat
gastroenter
symptom
noroviru
p
rotaviru
p
day
compar
addit
anecdot
studi
support
efficaci
ntz
treatment
noroviru
ntz
success
treat
one
immunosuppress
transplant
patient
infect
noroviru
experienc
consecut
day
gastroenter
four
day
commenc
ntz
treatment
complet
resolut
symptom
record
without
reduct
immunosuppress
ntz
treatment
also
shown
resolv
diarrheal
symptom
clear
noroviru
stool
sampl
pediatr
patient
chronic
noroviru
follow
kidney
although
studi
suggest
ntz
promis
therapi
treatment
noroviru
infect
equal
amount
evid
reveal
ntz
ineffect
noroviru
despit
contrari
evid
ntz
repres
therapeut
option
current
avail
apart
rbv
immunoglobulin
support
care
patient
persist
infect
human
noroviru
pervas
pathogen
creat
signific
social
econom
impact
caus
hundr
thousand
death
year
despit
intens
research
safe
effect
noroviru
antivir
none
yet
clinic
approv
major
candid
still
earli
stage
preclin
develop
review
outlin
recent
therapeut
candid
studi
provid
updat
overview
current
human
noroviru
antivir
develop
pipelin
optim
human
noroviru
cultur
enteroid
b
cell
system
offer
promis
time
robust
reliabl
cultur
method
develop
allow
greater
replic
level
improv
system
may
enhanc
antivir
studi
provid
stronger
platform
effect
noroviru
antivir
develop
landscap
antivir
develop
noroviru
chang
rapidli
develop
field
host
immunomodulatori
therapi
open
door
potenti
treatment
mani
viral
infect
promis
result
alreadi
publish
noroviru
moreov
recent
discoveri
report
highli
conserv
bind
pocket
critic
viral
enzym
noroviru
polymeras
could
allow
develop
antivir
author
declar
conflict
interest
